Concepts (185)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Thyroid Neoplasms | 9 | 2019 | 31 | 3.990 |
Why?
|
| Thyroidectomy | 8 | 2020 | 18 | 3.050 |
Why?
|
| Hyperthermia, Induced | 11 | 2015 | 246 | 2.420 |
Why?
|
| Neoplasm Recurrence, Local | 8 | 2019 | 369 | 2.260 |
Why?
|
| Peritoneal Neoplasms | 9 | 2014 | 262 | 1.920 |
Why?
|
| Hyperparathyroidism, Primary | 4 | 2018 | 9 | 1.910 |
Why?
|
| Parathyroidectomy | 5 | 2020 | 15 | 1.760 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 10 | 2014 | 158 | 1.530 |
Why?
|
| Adenocarcinoma, Follicular | 2 | 2019 | 2 | 1.280 |
Why?
|
| Retrospective Studies | 22 | 2020 | 3488 | 1.240 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 7 | 2014 | 461 | 1.170 |
Why?
|
| Lymph Node Excision | 2 | 2017 | 90 | 1.110 |
Why?
|
| Middle Aged | 30 | 2020 | 11824 | 1.100 |
Why?
|
| Carcinoma, Papillary | 4 | 2017 | 13 | 1.030 |
Why?
|
| Carcinoma, Neuroendocrine | 2 | 2016 | 13 | 1.020 |
Why?
|
| Female | 32 | 2020 | 19859 | 0.940 |
Why?
|
| Postoperative Complications | 4 | 2017 | 779 | 0.900 |
Why?
|
| Male | 29 | 2020 | 19091 | 0.880 |
Why?
|
| Thyroid Gland | 2 | 2019 | 15 | 0.840 |
Why?
|
| Adenocarcinoma | 2 | 2016 | 311 | 0.830 |
Why?
|
| Humans | 35 | 2020 | 31836 | 0.820 |
Why?
|
| Follow-Up Studies | 13 | 2019 | 2271 | 0.810 |
Why?
|
| Appendiceal Neoplasms | 4 | 2015 | 98 | 0.770 |
Why?
|
| Hyperparathyroidism | 1 | 2020 | 8 | 0.740 |
Why?
|
| Aged | 18 | 2020 | 10288 | 0.740 |
Why?
|
| Adult | 17 | 2020 | 9327 | 0.740 |
Why?
|
| Neoplasm Staging | 10 | 2019 | 456 | 0.740 |
Why?
|
| Neoplasms | 4 | 2014 | 692 | 0.720 |
Why?
|
| Combined Modality Therapy | 10 | 2019 | 564 | 0.680 |
Why?
|
| Thyroid Nodule | 1 | 2019 | 7 | 0.680 |
Why?
|
| Hashimoto Disease | 1 | 2019 | 1 | 0.680 |
Why?
|
| Faculty, Medical | 1 | 2020 | 78 | 0.680 |
Why?
|
| Survival Rate | 10 | 2019 | 884 | 0.670 |
Why?
|
| Surgical Procedures, Operative | 1 | 2020 | 82 | 0.670 |
Why?
|
| Adenocarcinoma, Papillary | 1 | 2019 | 2 | 0.670 |
Why?
|
| Autoantibodies | 1 | 2019 | 49 | 0.660 |
Why?
|
| Quality of Health Care | 1 | 2019 | 147 | 0.620 |
Why?
|
| Carcinoma, Medullary | 1 | 2017 | 1 | 0.620 |
Why?
|
| Potassium Iodide | 1 | 2017 | 1 | 0.610 |
Why?
|
| Graves Disease | 1 | 2017 | 5 | 0.610 |
Why?
|
| Hypercalcemia | 1 | 2017 | 9 | 0.590 |
Why?
|
| Prognosis | 9 | 2017 | 1498 | 0.580 |
Why?
|
| Clinical Competence | 1 | 2020 | 325 | 0.580 |
Why?
|
| Treatment Outcome | 9 | 2020 | 3294 | 0.570 |
Why?
|
| Emotions | 1 | 2017 | 56 | 0.570 |
Why?
|
| Fear | 1 | 2017 | 48 | 0.570 |
Why?
|
| Primary Health Care | 1 | 2019 | 225 | 0.570 |
Why?
|
| Phenoxybenzamine | 1 | 2016 | 2 | 0.560 |
Why?
|
| Doxazosin | 1 | 2016 | 2 | 0.560 |
Why?
|
| Pheochromocytoma | 1 | 2016 | 5 | 0.560 |
Why?
|
| Adrenalectomy | 1 | 2016 | 29 | 0.550 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2016 | 14 | 0.550 |
Why?
|
| Hypocalcemia | 1 | 2016 | 13 | 0.550 |
Why?
|
| Internship and Residency | 1 | 2020 | 306 | 0.540 |
Why?
|
| Choledochal Cyst | 1 | 2015 | 6 | 0.520 |
Why?
|
| Stomach Neoplasms | 1 | 2016 | 84 | 0.510 |
Why?
|
| Vitamin D Deficiency | 1 | 2016 | 89 | 0.510 |
Why?
|
| Preoperative Care | 1 | 2016 | 115 | 0.510 |
Why?
|
| Registries | 1 | 2016 | 295 | 0.500 |
Why?
|
| Laparoscopy | 1 | 2016 | 171 | 0.490 |
Why?
|
| Abdominal Cavity | 1 | 2014 | 6 | 0.480 |
Why?
|
| Abdominal Neoplasms | 1 | 2014 | 15 | 0.480 |
Why?
|
| Gallbladder Neoplasms | 1 | 2014 | 36 | 0.470 |
Why?
|
| Carcinoma | 1 | 2015 | 92 | 0.470 |
Why?
|
| Common Bile Duct Neoplasms | 1 | 2013 | 7 | 0.460 |
Why?
|
| Ampulla of Vater | 1 | 2013 | 7 | 0.460 |
Why?
|
| Duodenal Neoplasms | 1 | 2013 | 6 | 0.460 |
Why?
|
| Oncolytic Viruses | 1 | 2013 | 7 | 0.460 |
Why?
|
| Vesiculovirus | 1 | 2013 | 4 | 0.460 |
Why?
|
| Carcinoid Tumor | 1 | 2013 | 14 | 0.460 |
Why?
|
| Ascites | 1 | 2013 | 16 | 0.450 |
Why?
|
| Oncolytic Virotherapy | 1 | 2013 | 14 | 0.450 |
Why?
|
| Neuroendocrine Tumors | 1 | 2013 | 19 | 0.450 |
Why?
|
| Antineoplastic Agents | 2 | 2015 | 607 | 0.430 |
Why?
|
| Liver Neoplasms | 1 | 2014 | 159 | 0.430 |
Why?
|
| Sarcoma | 1 | 2013 | 71 | 0.420 |
Why?
|
| Case-Control Studies | 4 | 2016 | 895 | 0.390 |
Why?
|
| Diabetes Mellitus | 1 | 2014 | 409 | 0.380 |
Why?
|
| Young Adult | 7 | 2017 | 2603 | 0.380 |
Why?
|
| Survival Analysis | 3 | 2016 | 487 | 0.360 |
Why?
|
| Prospective Studies | 8 | 2017 | 2277 | 0.360 |
Why?
|
| United States | 4 | 2020 | 3925 | 0.330 |
Why?
|
| Risk Assessment | 3 | 2019 | 1431 | 0.300 |
Why?
|
| SEER Program | 2 | 2016 | 35 | 0.260 |
Why?
|
| Neoplasm Invasiveness | 2 | 2016 | 194 | 0.250 |
Why?
|
| Aged, 80 and over | 5 | 2016 | 3988 | 0.240 |
Why?
|
| Databases, Factual | 2 | 2016 | 349 | 0.240 |
Why?
|
| Diaphragm | 2 | 2014 | 40 | 0.240 |
Why?
|
| Postural Balance | 1 | 2016 | 182 | 0.230 |
Why?
|
| North Carolina | 3 | 2016 | 1514 | 0.230 |
Why?
|
| Colonic Neoplasms | 2 | 2014 | 71 | 0.220 |
Why?
|
| Pesticides | 1 | 2016 | 200 | 0.220 |
Why?
|
| Occupational Exposure | 1 | 2016 | 233 | 0.220 |
Why?
|
| Transients and Migrants | 1 | 2016 | 291 | 0.210 |
Why?
|
| Emigrants and Immigrants | 1 | 2016 | 245 | 0.210 |
Why?
|
| Chemotherapy, Adjuvant | 4 | 2014 | 192 | 0.200 |
Why?
|
| Child | 4 | 2017 | 2425 | 0.190 |
Why?
|
| Mentors | 1 | 2020 | 31 | 0.180 |
Why?
|
| Trust | 1 | 2020 | 43 | 0.180 |
Why?
|
| Health Plan Implementation | 1 | 2020 | 22 | 0.180 |
Why?
|
| Thyrotropin | 1 | 2019 | 8 | 0.170 |
Why?
|
| Ultrasonography | 2 | 2019 | 378 | 0.170 |
Why?
|
| Quality of Life | 2 | 2017 | 924 | 0.170 |
Why?
|
| Adolescent | 4 | 2017 | 3511 | 0.170 |
Why?
|
| Hispanic Americans | 1 | 2016 | 942 | 0.170 |
Why?
|
| Academic Medical Centers | 1 | 2020 | 156 | 0.160 |
Why?
|
| Guideline Adherence | 1 | 2019 | 119 | 0.160 |
Why?
|
| Societies, Medical | 1 | 2019 | 161 | 0.150 |
Why?
|
| Referral and Consultation | 1 | 2019 | 140 | 0.150 |
Why?
|
| Wisconsin | 1 | 2017 | 21 | 0.150 |
Why?
|
| Feasibility Studies | 2 | 2020 | 291 | 0.150 |
Why?
|
| Pain, Postoperative | 1 | 2020 | 178 | 0.150 |
Why?
|
| Parathyroid Glands | 1 | 2017 | 3 | 0.150 |
Why?
|
| Parathyroid Neoplasms | 1 | 2017 | 7 | 0.150 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 518 | 0.150 |
Why?
|
| Lymphatic Metastasis | 2 | 2014 | 170 | 0.150 |
Why?
|
| Mitomycin | 2 | 2014 | 52 | 0.150 |
Why?
|
| Cisplatin | 2 | 2014 | 77 | 0.150 |
Why?
|
| Statistics, Nonparametric | 1 | 2016 | 131 | 0.140 |
Why?
|
| Choristoma | 1 | 2016 | 16 | 0.140 |
Why?
|
| Teratoma | 1 | 2016 | 10 | 0.140 |
Why?
|
| Research Design | 1 | 2018 | 310 | 0.140 |
Why?
|
| Qualitative Research | 1 | 2017 | 166 | 0.140 |
Why?
|
| Interviews as Topic | 1 | 2017 | 262 | 0.140 |
Why?
|
| Preoperative Period | 1 | 2016 | 35 | 0.140 |
Why?
|
| Practice Guidelines as Topic | 1 | 2019 | 404 | 0.140 |
Why?
|
| Disease-Free Survival | 1 | 2016 | 319 | 0.130 |
Why?
|
| Abdomen | 1 | 2016 | 44 | 0.130 |
Why?
|
| Gastrectomy | 1 | 2016 | 67 | 0.130 |
Why?
|
| Hemodynamics | 1 | 2016 | 152 | 0.130 |
Why?
|
| Vitamins | 1 | 2016 | 68 | 0.130 |
Why?
|
| Cholangiopancreatography, Magnetic Resonance | 1 | 2015 | 8 | 0.130 |
Why?
|
| Dilatation, Pathologic | 1 | 2015 | 20 | 0.130 |
Why?
|
| Common Bile Duct | 1 | 2015 | 8 | 0.130 |
Why?
|
| Ovarian Neoplasms | 1 | 2016 | 94 | 0.130 |
Why?
|
| Intraoperative Care | 1 | 2015 | 48 | 0.120 |
Why?
|
| Neoplasm Metastasis | 1 | 2016 | 221 | 0.120 |
Why?
|
| Vitamin D | 1 | 2016 | 183 | 0.120 |
Why?
|
| Colectomy | 1 | 2014 | 23 | 0.120 |
Why?
|
| Pneumonia | 1 | 2014 | 66 | 0.120 |
Why?
|
| Omentum | 1 | 2014 | 26 | 0.120 |
Why?
|
| Thrombosis | 1 | 2014 | 72 | 0.120 |
Why?
|
| Pancreatectomy | 1 | 2014 | 32 | 0.120 |
Why?
|
| Multivariate Analysis | 1 | 2016 | 686 | 0.120 |
Why?
|
| Respiratory Insufficiency | 1 | 2014 | 57 | 0.120 |
Why?
|
| Intensive Care Units | 1 | 2014 | 109 | 0.120 |
Why?
|
| Hepatectomy | 1 | 2014 | 64 | 0.120 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2014 | 92 | 0.120 |
Why?
|
| Ovariectomy | 1 | 2014 | 149 | 0.110 |
Why?
|
| Viral Matrix Proteins | 1 | 2013 | 9 | 0.110 |
Why?
|
| Tumor Burden | 1 | 2013 | 60 | 0.110 |
Why?
|
| Interferon-beta | 1 | 2013 | 18 | 0.110 |
Why?
|
| Urinary Tract | 1 | 2013 | 22 | 0.110 |
Why?
|
| Urologic Diseases | 1 | 2013 | 27 | 0.110 |
Why?
|
| Hospital Mortality | 1 | 2014 | 190 | 0.110 |
Why?
|
| Length of Stay | 1 | 2014 | 315 | 0.110 |
Why?
|
| Peritoneum | 1 | 2013 | 33 | 0.110 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2013 | 114 | 0.110 |
Why?
|
| Incidence | 1 | 2016 | 1192 | 0.110 |
Why?
|
| Mice, Nude | 1 | 2013 | 290 | 0.110 |
Why?
|
| Proportional Hazards Models | 1 | 2013 | 756 | 0.100 |
Why?
|
| Cell Line, Tumor | 1 | 2013 | 725 | 0.100 |
Why?
|
| Mutation | 1 | 2013 | 487 | 0.090 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2015 | 912 | 0.090 |
Why?
|
| Risk Factors | 1 | 2016 | 3851 | 0.080 |
Why?
|
| Mice | 1 | 2013 | 2476 | 0.070 |
Why?
|
| Obesity | 1 | 2013 | 1158 | 0.060 |
Why?
|
| Animals | 1 | 2013 | 7450 | 0.050 |
Why?
|
| Hydrocodone | 1 | 2020 | 1 | 0.050 |
Why?
|
| Acetaminophen | 1 | 2020 | 19 | 0.040 |
Why?
|
| Drug Utilization | 1 | 2020 | 49 | 0.040 |
Why?
|
| Drug Combinations | 1 | 2020 | 93 | 0.040 |
Why?
|
| Drug Prescriptions | 1 | 2020 | 54 | 0.040 |
Why?
|
| Pain Measurement | 1 | 2020 | 351 | 0.040 |
Why?
|
| Patient Satisfaction | 1 | 2020 | 240 | 0.040 |
Why?
|
| Thyroglobulin | 1 | 2017 | 2 | 0.040 |
Why?
|
| Analgesics, Opioid | 1 | 2020 | 231 | 0.040 |
Why?
|
| Reoperation | 1 | 2017 | 226 | 0.040 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2014 | 9 | 0.030 |
Why?
|
| Injections, Intraperitoneal | 1 | 2014 | 44 | 0.030 |
Why?
|
| Morbidity | 1 | 2014 | 99 | 0.030 |
Why?
|
| Perfusion | 1 | 2014 | 73 | 0.030 |
Why?
|
| Carboplatin | 1 | 2013 | 48 | 0.030 |
Why?
|
| Organoplatinum Compounds | 1 | 2013 | 47 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2017 | 1259 | 0.030 |
Why?
|